Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 58 clinical trials
Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

-small cell lung cancer (NSCLC) who have disease progression following platinum-based chemotherapy and anti-programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) antibody, with

docetaxel
platinum-based chemotherapy
lung carcinoma
tyrosine
progressive disease
  • 2 views
  • 29 Apr, 2022
  • 63 locations
LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of Lerapolturev (PVSRIPO) and Lerapolturev in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors

This is a Phase 1/2, open-label, multi-center, single arm basket study evaluating the administration of lerapolturev ± anti programmed cell death protein 1 (PD 1)/programmed death-ligand 1 (PD

bladder tumor
carcinoma
immunomodulator
squamous cell carcinoma
cystoscopy
  • 0 views
  • 28 Jul, 2022
  • 1 location
To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

patients with advanced nasopharyngeal carcinoma who had previously failed platinum-based chemotherapy and immune checkpoint inhibitors (programmed cell death protein 1 (PD-1)/ Programmed death-ligand 1 (PD

  • 0 views
  • 24 Mar, 2022
  • 7 locations
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

)-engineered immunoglobulin G1 anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) human monoclonal antibody (botensilimab) monotherapy and in combination with an anti-programmed cell death protein-1 (PD-1

aptt
renal function
anticoagulant
platelet count
cancer
  • 15 views
  • 14 Jul, 2022
  • 14 locations
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

, and anti-tumor activity of PF-07263689, either alone or in combination with sasanlimab (an investigational anti-programmed cell death protein 1 [PD-1] antibody), in patients with selected locally

combination therapy
programmed cell death 1 ligand 1
growth factor
measurable disease
monoclonal antibodies
  • 0 views
  • 25 Mar, 2022
  • 3 locations
Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma.

There is increasing evidence that combination therapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and programmed cell death protein 1 (PD-1) inhibitor is safe and efficacious in

neutrophil count
epithelioid sarcoma
platelet count
growth factor
soft tissue sarcoma
  • 0 views
  • 25 Mar, 2022
Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma

tumor-associated macrophages and increased interferon-γ-producing cluster of differentiation 8+ (CD8+) T cells. Addition of programmed cell death protein 1 (PD-1)/programmed death-ligand (PD-L1

  • 12 views
  • 10 Aug, 2022
  • 1 location
TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation (ATOMICC) (ATOMICC)

) gained the same benefit that patients with partial response (PR). Due to the aforementioned biology of cervical cancer, the proven activity of anti programmed cell death protein 1 (Anti-PD1) agents in

anticoagulant
adenocarcinoma
cancer
durvalumab
recurrent cervical cancer
  • 34 views
  • 12 Feb, 2022
  • 25 locations
BEACON - ABC in Recurrent Platinum Resistant HGSOC (BEACON)

tumours. Atezolizumab is a type of drug called a Programmed Cell Death Protein 1 (PD-L1) inhibitor. PD-L1 binds to PD-1 which is a type of protein found on the surface of cells in your body's

cytoreductive surgery
cancer antigen 125
carcinosarcoma
ovarian cancer
platelet count
  • 30 views
  • 14 Feb, 2022
  • 1 location
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).

  • 0 views
  • 09 Aug, 2022
  • 2 locations